Philippe Camus, M.D.
Dijon, France
The drug was recalled in 2009-2010
Valvular heart disease and/or dysfunction
Evidence level
definite
Pulmonary arterial hypertension
possible
Pleural effusion (uni or bilateral) (can accompany ILD induced by the drug)
low
Pleural thickening - Fibrothorax